Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide

Figure 2

Effect of disease risk index on (a) disease-free survival and (b) relapse following MA haplo-HSCT.

(a)

(b)